Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses.

The research studied how three specific medications impact the production of thromboxane and prostacyclin in healthy horses. Of the three, flunixin proved to be the most effective inhibitor.

Research Aim

• The study was designed to gauge the effectiveness of three different drugs – flunixin meglumine, phenylbutazone, and a selective thromboxane synthetase inhibitor, UK-38,485 – in modifying the metabolism of arachidonic acid in healthy horses. Arachidonic acid metabolism is responsible for the production of prostacyclin (PGI2) and thromboxane A2 (TxA2).

Methodology

• A dose response evaluation was performed to see how these drugs respond in varying doses.
• Radioimmunoassay, a scientific method used to measure tiny amounts of substances within a system, was utilised in assessing the concentrations of thromboxane A2 and prostacyclin in serum. This was done via measuring thromboxane B2 (TxB2) and 6-keto prostaglandin F1 alpha (6-keto PGF1 alpha), respective counterparts of TxA2 and PGI2.

Findings

• Between flunixin and phenylbutazone, the former was found to be more potent as an inhibitor of thromboxane and prostacyclin production.
• The thromboxane synthetase inhibitor, UK-38,485, also decreased levels of thromboxane but notably increased the levels of prostacyclin. This signified its selectivity as a thromboxane synthetase inhibitor.

Importance of the Study

• This research further our understanding of how certain drugs can alter the production of crucial body chemicals like thromboxane and prostacyclin, which play key parts in clot formation and blood vessel function.
• In veterinary medicine, it can help define the effectivity of these drugs in treating conditions involving heart rate, blood pressure, and other cardiovascular functionalities in horses.